

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



廣州白雲山醫葯集團股份有限公司

GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD.

(a joint stock company with limited liability established in the People's Republic of China)

(H Share Stock Code: 0874)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2020

Reference is made to the annual report of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) for the year ended 31 December 2020 (the “**Annual Report**”). Unless otherwise stated, capitalised terms used herein shall have the same meanings as defined in the Annual Report.

In addition to the information disclosed in the section headed “Notes to the Financial Statements” in the Annual Report, the board (the “**Board**”) of the Company hereby provides further information in relation to the basic pension insurance (the “**Basic Pension Insurance Plan**”) paid by the domestic enterprises of the Company according to the relevant regulations of the local government, the mandatory provident fund contribution (the “**Mandatory Provident Fund Contribution Plan**”) provided by the Company’s wholly-owned subsidiary, Guangzhou Pharmaceuticals Baiyunshan Hong Kong Company, in accordance with the Mandatory Provident Fund Schemes Ordinance of Hong Kong, and the enterprise annuity plans (the “**Enterprise Annuity Plan**”) established by part of the domestic enterprises of the Company based on the relevant policies of the national enterprise annuity system as stated in the Annual Report pursuant to paragraph 26(2) of Appendix 16 to the Listing Rules.

As at 31 December 2019 and 2020, there were no relevant forfeited contributions in the Group under the Basic Pension Insurance Plan and the Mandatory Provident Fund Contribution Plan. Under the Enterprise Annuity Plan, based on the relevant policies of the national enterprise annuity policy and the enterprise annuity system established by the Group, the company and part of affiliated companies that established the Enterprise Annuity Plan retain the forfeited contributions in the enterprise annuity public account for the benefit of employees who are still in the Enterprise Annuity Plan. The forfeited contributions will not be used to offset future contributions and will not reduce the current and future levels of contributions.

The above further information does not affect any other information contained in the Annual Report. Save as disclosed in this announcement, all other information contained in the Annual Report remains unchanged.

The Board of
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited

Guangzhou, the PRC, 9 September 2021

As at the Announcement Date, the Board comprises Mr. Li Chuyuan, Mr. Yang Jun, Ms. Cheng Ning, Ms. Liu Juyan, Mr. Zhang Chunbo, Mr. Wu Changhai and Mr. Li Hong, as executive directors, and Mr. Wong Hin Wing, Ms. Wang Weihong, Mr. Chen Yajin, and Mr. Huang Min as independent non-executive directors.